Welcome to our dedicated page for ODYSSEY THERAPEUTICS SEC filings (Ticker: ODTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ODYSSEY THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ODYSSEY THERAPEUTICS's regulatory disclosures and financial reporting.
Odyssey Therapeutics, Inc. Schedule 13G shows that Lightspeed-affiliated entities report beneficial ownership of 3,608,443 shares of Odyssey Therapeutics common stock. The filing states this equals 7.6% of the class based on 47,174,156 shares outstanding as of May 11, 2026.
The report lists shared voting and dispositive power for the Lightspeed entities and is filed jointly by Lightspeed Venture Partners XV-B (Ignite), L.P., Lightspeed General Partner XV-B (Ignite), L.P., and Lightspeed Ultimate General Partner XV-B (Ignite), L.L.C.
SR One-affiliated funds filed a Schedule 13D reporting beneficial ownership of 3,794,883 shares of Odyssey Therapeutics common stock, representing 8.0% of the company. The stake is held across SR One Fund I Aggregator, SR One Co-Invest vehicles and AMZL, all controlled through SR One Capital Management and ultimately by Dr. Simeon George.
The position arose from Odyssey’s initial public offering of 15,500,000 shares at $18.00 per share and the automatic conversion of multiple preferred stock series and warrants into common stock immediately before the IPO closing. The filing states the investment is for investment purposes, with no current plans for corporate changes.
The funds have registration rights under an Investors' Rights Agreement, including demand and piggyback rights, and are subject to a 180-day lock-up from May 7, 2026 that restricts sales, hedging and registration demands during that period.
TPG-affiliated investors have disclosed a significant new stake in Odyssey Therapeutics, Inc. Funds managed through TPG GP A, LLC now beneficially own 3,690,146 shares of Odyssey common stock, representing about 7.8% of the 47,174,156 shares outstanding as of the IPO closing.
The position includes 1,388,889 shares that TPG LSI Rise Orazio II, L.P. bought directly from Odyssey for $25,000,002 in a concurrent private placement at $18.00 per share, matching the initial public offering price. An Investors' Rights Agreement grants registration rights for resale of these shares, and the filing notes TPG may later consider actions involving Odyssey's operations, capital structure or additional share transactions.